Close Menu

BMS

The headline and this story have been updated to reflect that BMS and Lilly have submitted to the FDA retrospective analysis on Erbitux's efficacy in colorectal cancer patients with wild-type KRAS mutations, which the agency may use to update the drug label.

By Adam Bonislawski
Two papers published in the current edition of Nature Biotechnology add significantly to the publicly available data on the specificity of kinase inhibitors.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Bristol Myers-Squibb and Saladax Biomedical today expanded an agreement covering companion diagnostics to include Johnson & Johnson's Ortho-Clinical Diagnostics.

Pages

The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.

US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.

Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.

In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.